India Pharma Outlook Team | Thursday, 19 November 2026
The US Food and Drug Administration (FDA) has approved Sanofi’s Infilbray (venglustat), the first drug specifically designed to treat neurological symptoms of Type 3 Gaucher disease.
The decision marks an important milestone for patients who have long faced limited options for managing complications affecting the brain and nervous system.
Gaucher disease is a rare inherited disorder that prevents the body from properly breaking down certain fatty substances, causing them to accumulate in organs and the brain. Infilbray’s ability to cross the blood-brain barrier could address a longstanding gap in treatment.
Type 3 Gaucher disease differs from Type 1 because it also affects the central nervous system. Patients can experience progressive difficulties with balance, coordination, speech, memory, and thinking.
Existing enzyme replacement therapies, including Sanofi’s Cerezyme, help control symptoms outside the brain. However, they cannot adequately address neurological complications because they do not effectively reach the brain.
Infilbray takes a different approach. It works as an oral glucosylceramide synthase inhibitor, reducing the production and accumulation of harmful fatty substances throughout the body and brain.
Key details of the treatment include:
This approach could expand treatment options for patients whose neurological symptoms continue despite existing therapies.
Also Read: 5 Women Leaders Driving India's Pharma and Healthcare Innovation
The FDA based its decision on a 52-week clinical study involving 43 patients aged 12 and older. Researchers compared once-daily Infilbray with intravenous enzyme replacement therapy administered every two weeks.
Patients receiving Infilbray showed improvements in a combined measure of muscle control, coordination, and cognitive function compared with the enzyme replacement group.
However, the treatment carries important safety considerations. Common side effects include:
The approval gives patients with Gaucher disease a new option for neurological care, but it does not represent a cure. Long-term benefits and safety require continued evaluation. Sanofi also seeks regulatory approval in Europe and Japan, potentially expanding access to this treatment.
The approval also comes as Sanofi looks to diversify its drug portfolio under new CEO Belen Garijo. The company aims to reduce its reliance on blockbuster asthma drug Dupixent, which faces the loss of key patent exclusivity by the early 2030s. Expanding its rare disease portfolio with treatments such as Infilbray could support this broader strategy.